The Nameserver ns1.bms.com have a IP Address of 198.155.167.250 which is hosted on United States.
Learn more about Bristol-Myers Squibb and our mission to discover, develop and deliver innovative medicines to patients with serious diseases.
OPDIVO® (nivolumab), for patients with previously treated metastatic non-small cell lung cancer (NSCLC). See Indication and Important Safety Information.
OPDIVO® (nivolumab), for the treatment of patients with classical Hodgkin Lymphoma (cHL) that has relapsed or progressed after autologous HSCT and brentuximab vedotin or after...